ABSTRACT
Nineteen patients with bronchopulmonary infection and myasthenia gravis were enrolled in the study. The microbiological analysis of the specimens of phlegm and bronchial secretion revealed both grampositive and gramnegative bacteria. All the isolates were susceptible to the antibiotic used (cefoperazone/sulbactam). Intravenous immunoglobulins (IvIgs) were used to increase the treatment efficacy, to opsonize the infection foci and to decrease the hospitalization terms. The antibiotic therapy and simultaneous use of intravenous immunoglobulins provided higher clinical efficacy in 16 out of 19 patients (84.2%).
Subject(s)
Anti-Bacterial Agents/therapeutic use , Bronchopneumonia/drug therapy , Cefoperazone/therapeutic use , Immunoglobulins, Intravenous/therapeutic use , Myasthenia Gravis/drug therapy , Pneumonia, Bacterial/drug therapy , Sulbactam/therapeutic use , Adult , Aged , Aged, 80 and over , Bronchopneumonia/complications , Bronchopneumonia/immunology , Bronchopneumonia/microbiology , Drug Therapy, Combination , Female , Gram-Negative Bacteria/drug effects , Gram-Negative Bacteria/growth & development , Gram-Positive Bacteria/drug effects , Gram-Positive Bacteria/growth & development , Humans , Male , Middle Aged , Myasthenia Gravis/complications , Myasthenia Gravis/immunology , Myasthenia Gravis/microbiology , Pneumonia, Bacterial/complications , Pneumonia, Bacterial/immunology , Pneumonia, Bacterial/microbiology , Treatment OutcomeABSTRACT
The results of the clinico-microbiological investigation of the levofloxacin efficacy in the treatment of 38 patients with respiratory infections or various pyo-inflammatory lesions are presented. The positive results were stated in 29 (76.3%) patients. No adverse reactions were observed.
